<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879099</url>
  </required_header>
  <id_info>
    <org_study_id>73654</org_study_id>
    <secondary_id>Eudra CT 2008-007324-26</secondary_id>
    <nct_id>NCT00879099</nct_id>
  </id_info>
  <brief_title>Interaction Study of Timolol Eye Drops and Paroxetine Capsules</brief_title>
  <official_title>The Effect of Paroxetine on the Plasma Levels of Timolol Using Ophthalmic 0.5% Timolol Eye Drops and 0.1% Timolol Eye Gel in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Oy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Oy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the effect of antidepressant paroxetine, on the plasma
      levels of timolol and its main metabolites after topical application of ophthalmic timolol
      products.

      This will be a phase I, randomised, 4-phase cross-over study in healthy volunteers. Healthy
      male volunteers aged 18 - 40 years will be enrolled.

      Placebo or paroxetine will be given for three days after which 1 drop of timolol product will
      be administered once in both eyes.

      The duration of the paroxetine or placebo treatment period will be 3 days. There will be four
      different treatment periods. A washout between the study periods will be at least 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary parameters will be timolol area under the plasma drug concentration-time curve (AUC0-12h) and highest drug concentration observed in plasma (Cmax).</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Paroxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelatine capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol 0.5 % eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timosan 0.1% eye gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.</description>
    <arm_group_label>Paroxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.</description>
    <arm_group_label>Gelatine capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>timolol maleate</intervention_name>
    <description>Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.</description>
    <arm_group_label>Timolol 0.5 % eye drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>timolol maleate</intervention_name>
    <description>Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.</description>
    <arm_group_label>Timosan 0.1% eye gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male

          -  18 - 40 years of age

          -  be in good general health

          -  be willing to follow instructions

          -  provide a written informed consent

          -  have a BMI of 18.5 - 26

          -  have systolic blood pressure at least 105 mmHg

          -  have haemoglobin at least 135 g/l.

        Exclusion Criteria:

          -  known hypersensitivity to timolol, paroxetine or any component of the study
             medications

          -  any contraindications to timolol treatment including asthma and obstructive lung
             disease

          -  any contraindications to paroxetine treatment

          -  have heart rate 50/min or less in rest

          -  any regular medication

          -  allergy requiring antihistamine or ocular or nasal treatment

          -  clinically significant abnormalities (from normal limits) in laboratory values: basic
             blood count, creatinine, ALAT, AFOS, gamma-GT, K, Na

          -  clinically significant EKG abnormalities assessed by the investigator

          -  blood donation within the last 60 days (the required time period between two donations
             for men given by RedCross Finland).

          -  participation in another clinical trial involving an investigational drug/device, or
             participation in such trial within the last 60 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janne Backman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinica Pharmacology, Institute of Clinical Medicine, University of Helsinki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Helsinki, Department of Clinical Pharmacology</name>
      <address>
        <city>Helsinki</city>
        <state>Biomedicum</state>
        <zip>00014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2009</study_first_submitted>
  <study_first_submitted_qc>April 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2009</study_first_posted>
  <last_update_submitted>January 27, 2010</last_update_submitted>
  <last_update_submitted_qc>January 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Auli Ropo</name_title>
    <organization>Study director</organization>
  </responsible_party>
  <keyword>Interaction</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>Interaction study for healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

